|
Friday, December 10, 2021, Atlanta, GA, 11:30 AM – 1:30 PM Eastern Time
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma (Part 2 of a 4-Part Series)A Friday Satellite Symposium and Virtual Event Preceding the 63rd ASH Annual Meeting
Location
Omni Atlanta Hotel at CNN Center 190 Marietta St NW Atlanta, GA 30303 Hotel Phone: (404) 659-0000 Program Schedule — Eastern Time 11:00 AM – 11:30 AM — Registration and Lunch 11:30 AM – 1:30 PM — Educational Meeting Meeting Room International Ballroom (E-F) - North Tower (M2 Floor) This event will be webcast live. Please see Registration tab for details. Faculty
Jeremy Abramson, MD Director, Center for Lymphoma Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Martin Dreyling, MD, PhD Professor of Medicine III LMU University Hospital Munich Dept of Medicine III Munich, Germany Loretta J Nastoupil, MD Associate Professor Section Chief, Indolent Lymphoma Section Chief, New Drug Development Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, Texas Gilles Salles, MD, PhD Service Chief, Lymphoma Service Memorial Sloan Kettering Cancer Center New York, New York Moderator Ann S LaCasce, MD, MMSc Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology Associate Professor of Medicine, Harvard Medical School Lymphoma Program Dana-Farber Cancer Institute Boston, Massachusetts This activity is supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly and Seagen Inc.
Program Schedule — Eastern Time
11:00 AM – 11:30 AM — Registration and Lunch 11:30 AM – 1:30 PM — Educational Meeting MODULE 1: Diffuse Large B-Cell Lymphoma MODULE 2: Follicular Lymphoma MODULE 3: Mantle Cell Lymphoma MODULE 4: Current and Potential Future Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma MODULE 5: Hodgkin Lymphoma Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Abramson — Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc. Prof Dreyling — Research Support (to Institution): AbbVie Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc; Scientific Advisory Board: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Genmab, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, MorphoSys, Novartis, Roche Laboratories Inc; Speaker Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc. Dr Nastoupil — Advisory Committee: ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc. Dr Salles — Advisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc.MODERATOR — Ann S LaCasce, MD, MMSc – No relevant conflicts of interest to disclose. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly and Seagen Inc. Omni Atlanta Hotel at CNN Center Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 11:00 AM on Friday, December 10th. If you are interested in attending, please visit our registration desk located outside the International Ballroom (E-F) - North Tower (M2 Floor) of the Omni Atlanta Hotel at CNN Center hotel (190 Marietta St NW) within walking distance of the Georgia World Congress Center. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the ASH Conference. Registration for live broadcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|